Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - zolpidem tartrate is indicated for the short term treatment of insomnia in adults (see dosage and administration).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - short-term treatment of insomnia in adults.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep initiation and maintenance disorders - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; maize starch - adjunctive therapy for the short term management of insomnia in adults.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; microcrystalline cellulose; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; microcrystalline cellulose; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Iżrael - Ingliż - Ministry of Health

sanofi israel ltd - zolpidem tartrate - film coated tablets - zolpidem tartrate 10 mg - zolpidem - zolpidem - indications are limited to treatment of severe sleep disorders in the following cases: - occasional insomnia - transient insomnia.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - suvorexant, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; copovidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - belsomra is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. following initiation of treatment, continuation should be re-evaluated after 3 months [see pharmacodynamic properties, clinical trials and adverse effects (undesirable effects) for clinical trial durations].

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - suvorexant, quantity: 15 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; copovidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - belsomra is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance.,following initiation of treatment, continuation should be re-evaluated after 3 months [see pharmacodynamic properties, clinical trials and adverse effects (undesirable effects) for clinical trial durations].